Judge: Only One Plaintiff for Upcoming Bellwether Trial Over J&J Talc
U.S. District Judge Michael Shipp, in New Jersey, struck down a proposal from plaintiffs' lawyers in lawsuits over Johnson & Johnson's talcum powder to consolidate two cases for the first federal bellwether trial.Report: Firms Should Focus on Collections to Prepare for Uncertain 2025
"If firms are prepared for a softening demand economy, and are surprised that demand is strong, they're going to be in better shape than if they plan for future demand and find that it's weak," said Thomson Reuters analyst Bill Josten.Personal Liability Following a Deed in Lieu of Foreclosure in New Jersey
"This makes a deed in lieu of foreclosure an attractive loss mitigation option for a defaulting homeowner in New Jersey," writes Myron C. WeinsteinClass-Action Suit Filed Against Jaguar for Claims of Defective Windshields in Land Rover Defender
This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in federal and state courts.Jury Awards $1.5 Million Over Construction Worker's Fall Into Collapsed Trench
"Thus, the trench was permitted to exist in a dangerous condition while subcontractor workers were active on the jobsite and in the vicinity of the trench," the plaintiff's attorneys said.Preparing Your Law Firm for 2025: Smart Ways to Embrace AI & Other Technologies
Join the webcast to explore how transformative technologies drive legal industry change and how to embrace them to avoid being left behind.Pinelands Commission Water Diversion Regulation Prompts Reaction From Community
"Perhaps Clayton's greatest concern is that the Regulation ... fails to meaningfully exempt non-consumptive diversions," writes Connell Foley's Ryan Benson.Fired In-House Lawyer Claims She Lost Job During Miscarriage Recovery
"The defendants also went to great lengths to invent bogus and pre-textual performance issues in an attempt to justify an otherwise unlawful termination," plaintiffs lawyer Matthew Luber said.Drugmaker Accused of Overhyping Proposed COVID Treatment Agrees to $3M Settlement
"Plaintiffs assert that lenzilumab's prospects of success were overstated, that defendants failed to disclose material adverse nonpublic information concerning the scientific merits of repurposing lenzilumab as a COVID treatment as part of a scheme to mislead investors into purchasing shares of Humanigen stock," U.S. District Judge William J. Martini said.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250